Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Tango Therapeutics, Inc. (TNGX)

Tango Therapeutics reports 82% response rate in pancreatic trial; plans 14% job cut

Mixed Impact 4 of 5 other Written later

Tango Therapeutics reported updated Phase 1/2 data for vopimetostat combined with Revolution Medicines' RAS(ON) inhibitors, with an 82% objective response rate in 22 efficacy-evaluable pancreatic cancer patients as of an August 20, 2026 data cutoff. The company also approved a strategic reprioritization on October 22, 2026, which includes reducing its workforce by approximately 14%, mostly in research, and deprioritizing novel target discovery. For shareholders, the data support a planned Phase 3 study, while the restructuring and the dose level 2 safety results add uncertainty.

Key points

  • Pancreatic cohort: 82% objective response rate (18 of 22), median PFS not yet reached, 9-month PFS rate of 88%, as of August 20, 2026
  • Dose level 2 (250 mg vopimetostat) was not well tolerated, with 3 dose-limiting toxicities in 2 of 4 safety-evaluable patients
  • Planned global randomized Phase 3 in front-line MTAP-deleted pancreatic cancer expected to start in the first half of 2027; NSCLC monotherapy data now expected in January 2027
  • Board approved reprioritization on October 22, 2026; approximately 14% workforce reduction, mostly in the research group

The filing

CompanyTango Therapeutics, Inc. (TNGX)
Form8-K, current report
Filed with the SECOct 23, 2026, 6:36 AM ET
Accession number0001193125-26-429423

Items reported: 7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 23, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.